Mengyuan Mu
https://www.nateko.lu.se/sv/mengyuan-mu - 2026-08-21
Filtyp
https://www.nateko.lu.se/sv/mengyuan-mu - 2026-08-21
https://www.mhm.lu.se/felicita-brusoni - 2026-08-21
https://www.lub.lu.se/internt/anna-carlsdotter - 2026-08-21
https://www.soch.lu.se/lupita-svensson - 2026-08-21
https://www.ses.lu.se/sara-licata - 2026-08-21
https://www.cec.lu.se/sv/cerina-rydalv - 2026-08-21
https://www.cec.lu.se/sv/sara-hakansson - 2026-08-21
https://www.mgeo.lu.se/mengyuan-mu - 2026-08-21
https://www.mgeo.lu.se/alexander-degener - 2026-08-21
https://www.mgeo.lu.se/cerina-rydalv - 2026-08-21
https://www.intramed.lu.se/markus-heidenblad - 2026-08-21
https://www.jur.lu.se/tereza-plackova - 2026-08-21
https://www.ehl.lu.se/peter-holmstrom - 2026-08-21
https://www.keg.lu.se/aditi-daeyi - 2026-08-21
https://www.ehl.lu.se/robin-porsfelt - 2026-08-21
https://www.innovation.lu.se/rickard-sjostrom - 2026-08-21
BACKGROUND: In Phase II/III trials, administration of quadrivalent human papillomavirus (HPV) (types 6/11/16/18) L1 virus-like-particle vaccine was highly effective in preventing HPV6/11/16/18-related cervical intraepithelial neoplasia and non-invasive cervical cancer in women aged 16-26 years who were naïve to these HPV types at enrollment. However, the makeup and extent of catch-up vaccination p
The objective of this study was to compare the safety and efficacy of carboplatin plus epirubicin and paclitaxel (TEC) to carboplatin and paclitaxel (TC), in the treatment of epithelial ovarian, peritoneal, or tubal carcinoma.. Between March 1999 and August 2001, 887 patients were randomized to receive six to nine cycles of paclitaxel (175 mg/m(2), 3 h intravenously) followed by carboplatin (AUC 5